Real Patient Cases
Patient 1
Consider adding Optune Gio for older patients like this one1
Patient 1
76 years old
Biopsy only
MGMT-methylated
- Married, 4 grandchildren
- Retired painter
- Supported by his wife and daughter
Real patient profile provided by Kellie Kopp, RN, BSN, OCN.
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Optune Gio + adjuvant chemotherapy initiated 6 weeks after chemoradiation
- Temozolomide completed after 7 monthly cycles at 150 mg/m2 (dosing due to fatigue and thrombocytopenia)
Side effect management
Chemoradiation Therapy
Effects: Minimal side effects reported; mild fatigue, and constipation. Patient reported continued fatigue and thrombocytopenia during monthly temozolomide
Management: Stool softener; temozolomide dose reduced from 200 mg/m2 to 150 mg/m2
Optune Gio
Effects: Reported that his face “was red, like a sunburn and hot to touch” after first initiating Optune Gio and wearing for 50 hours straight
Management: A short treatment break and reapplication of arrays. No further skin issues were reported. Readdressed usage and continued compliance with each visit
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Optune Gio + adjuvant chemotherapy initiated 6 weeks after chemoradiation
- Temozolomide completed after 7 monthly cycles at 150 mg/m2 (dosing due to fatigue and thrombocytopenia)
Side effect management
Chemoradiation Therapy
Effects: Minimal side effects reported; mild fatigue, and constipation. Patient reported continued fatigue and thrombocytopenia during monthly temozolomide
Management: Stool softener; temozolomide dose reduced from 200 mg/m2 to 150 mg/m2
Optune Gio
Effects: Reported that his face “was red, like a sunburn and hot to touch” after first initiating Optune Gio and wearing for 50 hours straight
Management: A short treatment break and reapplication of arrays. No further skin issues were reported. Readdressed usage and continued compliance with each visit
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient's MRI
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient's usage report1
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient 2
Younger adult women like this patient may be able to benefit from receiving Optune Gio in addition to adjuvant TMZ1
Patient 2
58, female
MGMT-unmethylated
- Married, 3 children
- Accountant at a car dealership
- Caregiver for her sister
Real patient profile provided by Kellie Kopp, RN, BSN, OCN.
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
Treatment with TTFields was started concurrently with temozolomide for 12 months
- Concurrent temozolomide with Optune Gio for 12 months
- Subsequent biopsy with LITT was performed; pathology report noted reactive changes and no tumor
Chemotherapy
- Monthly temozolomide for 11 months*
- 3 months of 200 mg/m2
- 8 months of 75 mg/m2
- 6 weeks on, 2 weeks off for 4 cycles
- 6 weeks on, 2 weeks off for 4 cycles
*Prior to LITT, patient received a total of 11 months of TMZ, including standard dosing, followed by a lower dose of TMZ.
Side effect management
Chemoradiation Therapy
Effects: Fatigue, decreased appetite, constipation
Management: Laxative and stool softener plus referral to a dietitian
Optune Gio
Effects: One incident of superficial skin redness without any open areas of drainage
Management: Patient was counseled on scalp care. Good scalp hygiene was reinforced. Patient was encouraged to take short breaks from treatment
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
Treatment with TTFields was started concurrently with temozolomide for 12 months
- Concurrent temozolomide with Optune Gio for 12 months
- Subsequent biopsy with LITT was performed; pathology report noted reactive changes and no tumor
Chemotherapy
- Monthly temozolomide for 11 months*
- 3 months of 200 mg/m2
- 8 months of 75 mg/m2
- 6 weeks on, 2 weeks off for 4 cycles
- 6 weeks on, 2 weeks off for 4 cycles
*Prior to LITT, patient received a total of 11 months of TMZ, including standard dosing, followed by a lower dose of TMZ.
Side effect management
Chemoradiation Therapy
Effects: Fatigue, decreased appetite, constipation
Management: Laxative and stool softener plus referral to a dietitian
Optune Gio
Effects: One incident of superficial skin redness without any open areas of drainage
Management: Patient was counseled on scalp care. Good scalp hygiene was reinforced. Patient was encouraged to take short breaks from treatment
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient's MRI
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
Patient's usage report1
Case information used with permission from Kellie Kopp, RN, BSN, OCN.
MGMT, O-6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; ED, emergency department; WHO, World Health Organization; MRI, magnetic resonance imaging.
Reference: 1. Novocure Data on File OPT-05289.
Patient 3
For patients like this one, Optune Gio may play a role in delaying the progression that is common in GBM1
Patient 3
41, female
IDH1-mutated
Real patient profile provided by Volker Stieber, MD.
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Patient started Optune Gio together with 6 months of adjuvant temozolomide
Side effect management
Chemoradiation Therapy
Effects: Scalp alopecia and mild fatigue
Management: None reported
Optune Gio
Effects: None reported
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Patient started Optune Gio together with 6 months of adjuvant temozolomide
Side effect management
Chemoradiation Therapy
Effects: Scalp alopecia and mild fatigue
Management: None reported
Optune Gio
Effects: None reported
Case information used with permission from Volker Stieber, MD.
Patient's MRI
Case information used with permission from Volker Stieber, MD.
Patient 4
Adding Optune Gio can help provide long-term clinical outcomes for patients like this one1
Patient 4
61, female
2-year Optune Gio user
- Married
Real patient profile provided by Gautam Prasad, MD, PhD.
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Optune Gio was started after initial chemotherapy and administered concomitantly with maintenance temozolomide for 1 year
- Patient has continued using Optune Gio for an additional year
Side effect management
Chemoradiation Therapy
Effects: Mild left temporal alopecia with associated scalp dermatitis; mild nausea
Management: Prescribed antiemetics
Optune Gio
Effects: Intermittent mild dermatitis, particularly over the craniotomy scar
Management: Prescribed topical steroids
Current medical status
Continued treatment with Optune Gio
Optune Gio + adjuvant chemotherapy
- Optune Gio was started after initial chemotherapy and administered concomitantly with maintenance temozolomide for 1 year
- Patient has continued using Optune Gio for an additional year
Side effect management
Chemoradiation Therapy
Effects: Mild left temporal alopecia with associated scalp dermatitis; mild nausea
Management: Prescribed antiemetics
Optune Gio
Effects: Intermittent mild dermatitis, particularly over the craniotomy scar
Management: Prescribed topical steroids
Case information used with permission from Gautam Prasad, MD, PhD.
Patient's MRI
Case information used with permission from Gautam Prasad, MD, PhD.
Patient's usage report1
Case information used with permission from Gautam Prasad, MD, PhD.
MGMT, O-6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; ED, emergency department; WHO, World Health Organization; MRI, magnetic resonance imaging.
Reference: 1. Novocure Data on File OPT-05289.